[The efficacy and safety of Mexidol Forte 250 as part of long-term sequential therapy in patients with carotid stroke]. / Éffektivnost' i bezopasnost' preparata Meksidol Forte 250 v ramkakh dlitel'noi posledovatel'noi terapii u bol'nykh s ishemicheskim insul'tom v karotidnoi sisteme.

AIM: To evaluate an effect of long-term sequential therapy with mexidol and mexidol forte on the functional outcome of patients with carotid ischemic stroke. MATERIAL AND METHODS: The study included 50 patients with newly developed carotid stroke, hospitalized in the stroke unit on the first day from the onset of the disease. Patients of the main group (n=25) received mexidol in a dose of 500 mg intravenously once a day for 14 days, then mexidol forte 250 in tabs 250 mg 3 times a day for 60 days. Patients of the comparison group (n=25) received standard basic therapy. The significance of intergroup differences was assessed using the Mann-Whitney test, Fisher's exact test, and relative risk (OR) calculation. Differences were considered significant at a level of p<0,05. RESULTS: After 14 days of therapy, both groups of patients showed a positive trend compared to baseline. At the same time, patients of the mexidol group had a higher MoCA score (U=173,5, p=0,006), a lower score when performing tasks on dynamic praxis (U=214,0, p=0,028) and optical spatial disturbances (U=170,5, p=0,003), better memorization strength (181,5, p = 0,006) and better performance on abstraction MOCA subtest (U=200,5, p=0,014). By the 74th day, the absence of moderate cognitive impairment (MoCA> 26 points) was diagnosed in 17 patients (68%) of the main group and 14 patients (56%) of the comparison group. No significant differences were found. Moreover, patients of the main group had a significantly lower NIHSS score (U=124,0, p<0,001) and a lower degree of disability: a total mRS score 0-2 was achieved in 19 (76%) patients of the main group and only in 12 (48%) patients of the comparison group (OR=3,34, F=0,07, p<0,05). Also, patients receiving long-term sequential therapy with mexidol and mexidol forte 250 had milder spatial disorders than patients of the comparison group. CONCLUSION: Consecutive treatment with mexidol and mexidol forte 250 in the acute and early recovery periods of ischemic stroke positively affects the regression of local neurological symptoms, increases the likelihood of achieving independence in everyday life by 3,34 times, and reduces the severity of optical-spatial, neurodynamic and memory impairments.

[Mexidol in the rehabilitation of patients in the acute ischemic stroke]. / Meksidol v reabilitatsii bol'nykh v ostrom periode ishemicheskogo insul'ta.

UNLABELLED: Research objective - studying of results of a comprehensive neuro-rehabilitation patients in the acute ischemic stroke (according to the Samara regional vascular centre). MATERIAL AND METHODS: A review of the work of RVC on the main indicators for 2014, detailed analysis of 20 patients in the acute period of ischemic stroke, in which treatment was used the drug mexidol with the dynamics on standardized assessment scales (NIHSS, Rankin, Rivermead, MoCA, HADS). RESULTS AND DISCUSSION: The use of «Mexidol¼ in the treatment of stroke leads to a significant statistically and clinically significant improvement in cognitive, motor, sensory functions, reduction of fatigue, anxiety, improved adaptation to physical loads.